Platelets

We identified a novel potential therapeutic target for diseases characterized by alterations in the number or function of platelets. Those include Essential Thrombocytemia (ET), a subgroup of myeloproliferative neoplasms (MPN) due to somatic mutations occurring at the level of hematopoietic stem cells, in particular those stem cells primed to become megakaryocytes (Mk), the cells from which platelets are generated.